Literature DB >> 11527872

The promise and limits of private medicine: health policy dilemmas in Nigeria.

O Alubo1.   

Abstract

Developments in health are easily among the best known human development indicators. Comparisons of life expectancy, infant mortality, access to safe water and similar data indicate the positions of individual countries. The political and economic processes which these indices reflect, or which inform the nature of health policy, are often not as clear or visible. These structural factors are either frequently ignored or mentioned only in passing, as illustrated in a recent paper published in this journal on the private medical enterprise in Nigeria (Ogunbekun et al. 1999). According to the authors, the generally low quality of public health services and high user fees have combined to make private medicine the 'unavoidable choice' of Nigerians. They identify benefits of private medicine as higher technical efficiency and contributing to fill the gap created by inadequate public sector services and to medical training. This paper argues that these claims are exaggerated, and that the authors seem to ignore Nigeria's political and economic processes, the health seeking behaviour of Nigerians, as well as the prevailing causes of morbidity and mortality. It is suggested that whereas the contributions of private medicine are significant, there are also several limitations, some of which originate from its for-profit raison d'être. The ultimate aim of health development must include improved access to services and better health status for the majority of the people. Without any form of public supported programme of payments in Nigeria, these objectives are circumscribed, especially with high fees in the private system. It is concluded that while private medicine will continue to be available for those who can afford it, it is unlikely to provide solutions to Nigeria's morbidity and mortality problems, particularly in relation to epidemics such as the growing burden of HIV/AIDS.

Entities:  

Mesh:

Year:  2001        PMID: 11527872     DOI: 10.1093/heapol/16.3.313

Source DB:  PubMed          Journal:  Health Policy Plan        ISSN: 0268-1080            Impact factor:   3.344


  8 in total

1.  Patent medicine vendors, community pharmacists and STI management in Abuja, Nigeria.

Authors:  A D Okonkwo; U P Okonkwo
Journal:  Afr Health Sci       Date:  2010-09       Impact factor: 0.927

Review 2.  Child health: reaching the poor.

Authors:  Adam Wagstaff; Flavia Bustreo; Jennifer Bryce; Mariam Claeson
Journal:  Am J Public Health       Date:  2004-05       Impact factor: 9.308

3.  A review of management of infertility in Nigeria: framing the ethics of a national health policy.

Authors:  Oluyemi Akinloye; Ernest J Truter
Journal:  Int J Womens Health       Date:  2011-08-11

4.  Investigating determinants of catastrophic health spending among poorly insured elderly households in urban Nigeria.

Authors:  Olumide Adisa
Journal:  Int J Equity Health       Date:  2015-09-15

5.  Exploring the threshold premium for viable community based health insurance schemes in Nigeria.

Authors:  Emeka Ihechi Udeh; Obinna Emmanuel Onwujekwe; David Ayobami Adewole; Chima Ariel Onoka
Journal:  BMC Res Notes       Date:  2016-08-02

6.  Overdependence on For-Profit Pharmacies: A Descriptive Survey of User Evaluation of Medicines Availability in Public Hospitals in Selected Nigerian States.

Authors:  Boniface Ayanbekongshie Ushie; David Betelwhobel Ugal; Justin Agorye Ingwu
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

7.  Ease and equity of access to free DR-TB services in Nigeria- a qualitative analysis of policies, structures and processes.

Authors:  Charity Oga-Omenka; Florence Bada; Aderonke Agbaje; Patrick Dakum; Dick Menzies; Christina Zarowsky
Journal:  Int J Equity Health       Date:  2020-12-10

8.  Life in the buffer zone: Social relations and surplus health workers in Uganda's medicines retail sector.

Authors:  Eleanor Hutchinson; Sunday Mundua; Lydia Ochero; Anthony Mbonye; Sian E Clarke
Journal:  Soc Sci Med       Date:  2021-04-14       Impact factor: 5.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.